BioWorld

Sep. 22, 2009

View Archived Issues

Nektar Coffers Brimming with Cash Thanks to $1.5B Deal

Nektar Therapeutics Inc. will end the year flush with cash, after entering a deal valued at $1.5 billion with AstraZeneca plc. to develop a late-stage bowel drug candidate and a preclinical pain product. (BioWorld Today) Read More

Icagen, Pfizer Extend Deal; $1B in Milestones Still up for Grabs

Read More

BioCryst Gets More U.S. Funds for Peramivir, But Small Order

Read More

Good to the Bone: Denosumab Shines Again in Phase III Data

Read More

Analyst: Facet Investors Won't Bite on Biogen's Hostile Offer

Read More

1 H1N1 Shot Enough for Older Kids, But 2 Needed for Youngest

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More